
Investors Eye Moderna’s Future After Major Stock Drop: What’s Next?
Moderna’s stock recently dropped 17% following a business update, contributing to a 73% decline since mid-2024. Projected 2024 revenue is significantly reduced to $3–$3.1 billion, with 2025 estimates even lower at $1.5–$2.5 billion. The financial challenges reflect a volatile vaccine market, compounded